Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Total Revenue of $54.03 million for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $54.03M +48.0% |
$36.50M +36.1% |
$26.82M +88.4% |
$14.24M | $0.00 | $0.00 -100.0% |
| Revenue (ASC 606) | $54.03M +48.0% |
$36.50M +36.1% |
$26.82M +88.4% |
$14.24M | $0.00 | $0.00 -100.0% |
| Net Income | -$412.78M -161.3% |
$673.73M +291.4% |
-$352.09M -51.9% |
-$231.80M -114.4% |
$1.60B +590.2% |
-$327.37M +20.4% |
| Diluted EPS | -$7.12 -161.2% |
$11.64 +283.9% |
-$6.33 -49.6% |
-$4.23 -115.9% |
$26.55 +660.1% |
-$4.74 +30.9% |
| Total Assets | $1.30B -22.0% |
$1.66B +77.5% |
$937.12M -24.3% |
$1.24B -13.8% |
$1.44B +68.6% |
$852.95M -4.2% |
| Cash and Equivalents | $89.13M +16.9% |
$76.25M -13.6% |
$88.20M -36.7% |
$139.26M -31.4% |
$203.13M +59.4% |
$127.44M +57.5% |
| Stockholders Equity | $1.19B -22.6% |
$1.54B +90.0% |
$811.02M -26.3% |
$1.10B -14.8% |
$1.29B +223.4% |
$399.50M -37.6% |
| R&D Expense | $339.54M +12.7% |
$301.29M +1.9% |
$295.53M +5.6% |
$279.91M +8.9% |
$256.97M +16.4% |
$220.81M +3.1% |
| Operating Income | -$472.13M -10.9% |
-$425.74M -8.7% |
-$391.49M -0.6% |
-$389.05M -2.8% |
-$378.42M -12.7% |
-$335.92M -6.2% |
| Shares Outstanding | 58.45M +2.3% |
57.16M +2.2% |
55.95M +1.6% |
55.04M +1.3% |
54.33M -21.6% |
69.29M +1.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $12.88M | +43.7% | +3.4% |
| Revenue (ASC 606) | September 30, 2025 | $12.88M | +43.7% | +3.4% |
| Net Income | September 30, 2025 | -$103.43M | -110.9% | +7.7% |
| Diluted EPS | September 30, 2025 | -$1.78 | -111.0% | +7.8% |
| Total Assets | September 30, 2025 | $1.39B | -22.7% | -5.8% |
| Cash and Equivalents | September 30, 2025 | $92.71M | -63.5% | +14.6% |
| Stockholders Equity | September 30, 2025 | $1.28B | -21.0% | -6.2% |
| R&D Expense | September 30, 2025 | $86.80M | +19.8% | -5.6% |
| Operating Income | September 30, 2025 | -$116.87M | -13.7% | +8.0% |
| Shares Outstanding | September 30, 2025 | 58.28M | +2.2% | +0.4% |
- AGIOS PHARMACEUTICALS, INC. reported Total Revenue of $54.03 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +48.0% in Total Revenue compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $54.03 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +48.0% in Revenue (ASC 606) compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Net Income of -$412.78 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -161.3% in Net Income compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Diluted EPS of $7.12 per share (loss) for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -161.2% in Diluted EPS compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Total Assets of $1.30 billion for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -22.0% in Total Assets compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Cash and Equivalents of $89.13 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +16.9% in Cash and Equivalents compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.19 billion for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -22.6% in Stockholders Equity compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported R&D Expense of $339.54 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +12.7% in R&D Expense compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Operating Income of -$472.13 million for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -10.9% in Operating Income compared to the prior fiscal year.
- AGIOS PHARMACEUTICALS, INC. reported Shares Outstanding of 58.45 million shares for fiscal year 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +2.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: